Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Presentation TCT 2017

Aortic Valve Replacement for CHF

Presenter: Daniel Burkhoff, JoAnn Lindenfeld, Howard C. Herrmann

October 31, 2017

Presentation TCT 2017

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Presenter: Howard C. Herrmann, Michael J. Mack

October 31, 2017

Presentation TCT 2017

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Francesco Maisano

October 31, 2017

Presentation TCT 2017

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, David Meerkin

October 31, 2017

Presentation TCT 2017

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Maurice Buchbinder

October 31, 2017

Presentation TCT 2017

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Philippe Genereux

October 31, 2017

Presentation TCT 2017

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Mathew Williams

October 31, 2017

Presentation TCT 2017

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Nicolo Piazza

October 31, 2017

Presentation TCT 2017

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Vinayak Bapat

October 31, 2017

Presentation TCT 2017

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, David W.M. Muller

October 31, 2017

Presentation TCT 2017

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Anson Cheung

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Bernard Prendergast

October 31, 2017

Presentation TCT 2017

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Presenter: Howard C. Herrmann

October 30, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

CardiAQ

Presenter: Francesco Maisano, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

TAVR in Patients With CKD: Diagnostic Workup, Valve Sizing, and Other Procedural Adjustments

Presenter: Howard C. Herrmann

June 16, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

News Conference News CRT 2017

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Michael O'Riordan

February 27, 2017

Advertisement

Aortic Valve Replacement for CHF

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

CardiAQ

TAVR in Patients With CKD: Diagnostic Workup, Valve Sizing, and Other Procedural Adjustments

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content